Dynavax Technologies (DVAX) Competitors $12.85 -0.11 (-0.85%) (As of 12/16/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DVAX vs. HALO, IONS, ALKS, FOLD, GERN, LGND, MNKD, CLDX, BCRX, and NVAXShould you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), Ligand Pharmaceuticals (LGND), MannKind (MNKD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), and Novavax (NVAX). These companies are all part of the "biotechnology" industry. Dynavax Technologies vs. Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Amicus Therapeutics Geron Ligand Pharmaceuticals MannKind Celldex Therapeutics BioCryst Pharmaceuticals Novavax Dynavax Technologies (NASDAQ:DVAX) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Which has better earnings and valuation, DVAX or HALO? Halozyme Therapeutics has higher revenue and earnings than Dynavax Technologies. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDynavax Technologies$260.81M6.48-$6.39M$0.1398.85Halozyme Therapeutics$947.36M6.45$281.59M$3.0215.90 Do analysts recommend DVAX or HALO? Dynavax Technologies presently has a consensus price target of $22.00, suggesting a potential upside of 71.21%. Halozyme Therapeutics has a consensus price target of $61.11, suggesting a potential upside of 27.24%. Given Dynavax Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Dynavax Technologies is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dynavax Technologies 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Halozyme Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer DVAX or HALO? In the previous week, Halozyme Therapeutics had 13 more articles in the media than Dynavax Technologies. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 2 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 1.55 beat Halozyme Therapeutics' score of 1.17 indicating that Dynavax Technologies is being referred to more favorably in the media. Company Overall Sentiment Dynavax Technologies Very Positive Halozyme Therapeutics Positive Is DVAX or HALO more profitable? Halozyme Therapeutics has a net margin of 41.43% compared to Dynavax Technologies' net margin of 7.85%. Halozyme Therapeutics' return on equity of 179.82% beat Dynavax Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Dynavax Technologies7.85% 3.19% 2.02% Halozyme Therapeutics 41.43%179.82%23.56% Do institutionals and insiders believe in DVAX or HALO? 97.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 3.0% of Dynavax Technologies shares are held by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor DVAX or HALO? Halozyme Therapeutics received 50 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 69.47% of users gave Halozyme Therapeutics an outperform vote while only 65.87% of users gave Dynavax Technologies an outperform vote. CompanyUnderperformOutperformDynavax TechnologiesOutperform Votes47165.87% Underperform Votes24434.13% Halozyme TherapeuticsOutperform Votes52169.47% Underperform Votes22930.53% Which has more risk and volatility, DVAX or HALO? Dynavax Technologies has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. SummaryHalozyme Therapeutics beats Dynavax Technologies on 11 of the 18 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get Dynavax Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DVAX vs. The Competition Export to ExcelMetricDynavax TechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.69B$6.40B$4.99B$9.33BDividend YieldN/A3.06%4.87%4.02%P/E Ratio98.8510.62103.4117.61Price / Sales6.48299.511,291.3782.44Price / CashN/A56.6541.6938.32Price / Book2.675.414.854.93Net Income-$6.39M$150.96M$117.81M$225.47M7 Day PerformanceN/A-5.51%16.15%-0.01%1 Month Performance5.24%0.26%19.00%5.92%1 Year Performance-5.93%15.31%37.38%22.97% Dynavax Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DVAXDynavax Technologies4.8065 of 5 stars$12.85-0.8%$22.00+71.2%-5.9%$1.69B$260.81M98.85408Short Interest ↓News CoveragePositive NewsHALOHalozyme Therapeutics4.9965 of 5 stars$49.07+1.4%$61.11+24.5%+23.1%$6.24B$829.25M16.03390Short Interest ↓Positive NewsIONSIonis Pharmaceuticals4.4924 of 5 stars$38.77+1.7%$60.65+56.4%-23.3%$6.12B$788M0.00800Short Interest ↓Positive NewsALKSAlkermes4.6748 of 5 stars$31.56+0.3%$35.42+12.2%+11.9%$5.11B$1.66B16.132,100Short Interest ↓FOLDAmicus Therapeutics4.3966 of 5 stars$9.94+2.2%$17.63+77.3%-22.2%$2.97B$399.36M0.00480GERNGeron3.9243 of 5 stars$3.96+0.8%$7.05+78.0%+69.3%$2.39B$240,000.000.00141Short Interest ↓LGNDLigand Pharmaceuticals4.8918 of 5 stars$115.85-7.2%$144.83+25.0%+81.6%$2.19B$131.31M49.7380Analyst ForecastNews CoverageMNKDMannKind3.6398 of 5 stars$6.68-1.8%$8.67+29.7%+59.1%$1.84B$198.96M97.14400News CoverageCLDXCelldex Therapeutics3.0808 of 5 stars$26.50-1.0%$62.25+134.9%-29.5%$1.76B$6.88M-10.42160Positive NewsBCRXBioCryst Pharmaceuticals3.8977 of 5 stars$7.68+0.9%$15.60+103.1%+20.5%$1.59B$331.41M0.00530Positive NewsNVAXNovavax3.8975 of 5 stars$9.15+2.3%$17.83+94.9%+70.9%$1.47B$983.71M0.001,543 Related Companies and Tools Related Companies HALO Competitors IONS Competitors ALKS Competitors FOLD Competitors GERN Competitors LGND Competitors MNKD Competitors CLDX Competitors BCRX Competitors NVAX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DVAX) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
